Corbus Pharmaceuticals Holdings, Inc. financial data

Symbol
CRBP on Nasdaq
Industry
Pharmaceutical Preparations
Location
500 River Ridge Drive, Norwood, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
SAV Acquisition Corp (to 1/10/2014)
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 486 % +108%
Debt-to-equity 28.4 % -87.8%
Return On Equity -42.3 % +86.8%
Return On Assets -32.9 % +65.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 12.2M shares +175%
Common Stock, Shares, Outstanding 12.2M shares +175%
Entity Public Float 34.6M USD +9.84%
Common Stock, Value, Issued 1K USD +126%
Weighted Average Number of Shares Outstanding, Basic 12M shares +172%
Weighted Average Number of Shares Outstanding, Diluted 12M shares +172%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 30.4M USD -0.06%
General and Administrative Expense 15.8M USD +3.03%
Operating Income (Loss) -46.2M USD -0.98%
Nonoperating Income (Expense) 7.52M USD
Net Income (Loss) Attributable to Parent -38.7M USD +18.5%
Earnings Per Share, Basic -4.63 USD/shares +58.5%
Earnings Per Share, Diluted -4.63 USD/shares +58.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 19.4M USD +72.7%
Assets, Current 161M USD +416%
Property, Plant and Equipment, Net 519K USD -53.7%
Operating Lease, Right-of-Use Asset 2.38M USD -27.5%
Other Assets, Noncurrent 0 USD -100%
Assets 164M USD +352%
Accounts Payable, Current 2.89M USD -38.8%
Employee-related Liabilities, Current 1.82M USD +9.16%
Accrued Liabilities, Current 7.18M USD -4.9%
Liabilities, Current 11.6M USD -63.1%
Operating Lease, Liability, Noncurrent 2.05M USD -43.3%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 13.7M USD -62%
Accumulated Other Comprehensive Income (Loss), Net of Tax 207K USD
Retained Earnings (Accumulated Deficit) -467M USD -9.03%
Stockholders' Equity Attributable to Parent 150M USD +48137%
Liabilities and Equity 164M USD +352%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.97M USD +47.3%
Net Cash Provided by (Used in) Financing Activities 107M USD
Net Cash Provided by (Used in) Investing Activities -98.2M USD -1870%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 12.2M shares +175%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 379K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 20.1M USD +68.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 547K USD -14.7%
Deferred Tax Assets, Valuation Allowance 94.9M USD +12.8%
Deferred Tax Assets, Gross 94.9M USD +12.8%
Operating Lease, Liability 3.61M USD -27.9%
Depreciation 611K USD -20.3%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -38.5M USD +18.6%
Lessee, Operating Lease, Liability, to be Paid 3.92M USD -30.7%
Property, Plant and Equipment, Gross 4.53M USD +0.01%
Operating Lease, Liability, Current 1.56M USD +11.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.8M USD +2.72%
Lessee, Operating Lease, Liability, to be Paid, Year One 439K USD +2.82%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 312K USD -52%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.69M USD -5.96%
Deferred Tax Assets, Operating Loss Carryforwards 59.1M USD +10.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.69M USD 0%
Additional Paid in Capital 618M USD +44%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 5.31M USD +34.9%
Interest Expense 652K USD -35.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%